Condition: Non-Small Cell Lung Cancer · Sponsor: Abbisko Therapeutics Co, Ltd
This is a multicenter, open-label phase 2 study that will enroll KRASG12C mutated patients with locally advanced or metastatic NSCLC, receiving treatment (ABSK043 in combination with Glecirasib) in a 21-day combination cycle.
This description comes directly from the study's public registry record.
Yinan Lin · +86-21-68910052 · clinical@abbisko.cn
Always discuss trial participation with your own doctor first.
| The First Affiliated Hospital of Anhui Medical University | Hefei, Anhui, China | Not Yet Recruiting |
| Beijing Cancer Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Cancer Hospital Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Fujian Cancer Hospital | Fuzhou, Fujian, China | Recruiting |
| The First Affiliated Hospital of Sun Yat-sen University | Guangzhou, Guangdong, China | Recruiting |
| Guangxi Medical University Cancer Hospital & Guangxi Cancer Institude | Nanning, Guangxi, China | Not Yet Recruiting |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Recruiting |
| Henan Cancer Hospital | Zhengzhou, Henan, China | Not Yet Recruiting |
| Tongji Hospital Tongji Medical College of Hust | Wuhan, Hubei, China | Not Yet Recruiting |
| Hunan Cancer Hospitial | Changsha, Hunan, China | Recruiting |
| Zhongda Hospital Southeast University | Nanjing, Jiangsu, China | Recruiting |
| The First Hospital of China Medical University | Shenyang, Liaoning, China | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07164170